Ph 1/2 Program Initiated for Elraglusib in refractory melanoma and additional target solid tumor and heme cancers
“With the promising results we have seen with the IV formulation of elraglusib across an array of difficult-to-treat cancers, we are excited to advance the oral tablet formulation in additional indications, including patients with R/R metastatic melanoma,” said Dan Schmitt, Chief Executive Officer of Actuate Therapeutics. “Elraglusib oral tablet will allow us to further explore elraglusib dose using a convenient and easily administered tablet dosage form that will be amenable to evaluation as a single agent. The program builds on encouraging results from our phase 1 monotherapy clinical trial with the IV formulation, including a remarkable complete response lasting more than 6 years from a patient with highly advanced, highly disseminated, refractory BRAFV600E-mutated metastatic melanoma. We believe the elraglusib oral tablet will have the potential to play an important role in addressing a significant unmet need in the treatment of refractory melanoma as well as other advanced cancer indications.”
Share:
More News
“FDA clearance of the IND for ORM-1153 is an important milestone for Orum, bringing another first-in-class DAC into the clinic and extending our approach into CD123-expressing hematologic malignancies,” said Olaf Christensen, M.D., Chief Medical Officer of Orum Therapeutics. “By combining cell-selective delivery with targeted protein degradation in a single molecule,
“We are excited to expand our clinical collaboration with Roche to evaluate a second KRAS combination with potential best-in-class MTA-cooperative PRMT5 inhibitor IDE892 for pancreatic cancer patients, where there remains a high unmet medical need. IDEAYA is advancing multiple rational combination strategies for the IDE892 program, including with MAT2A inhibitor
“These encouraging initial safety observations represent an important first step in the clinical evaluation of ZI-MA4-1 and our TCR-NK platform” said Namir Hassan, Chief Executive Officer of Zelluna. “The first patient received all three planned doses, and the independent committee’s recommendation enables us to continue recruitment at the first dose
“Receiving FTD is an important milestone for ERAS-0015 and reflects the urgent need for new therapies for patients with metastatic pancreatic cancer,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “Together with the encouraging clinical activity and favorable tolerability observed to date, this FTD helps to position us